arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Edgewise Therapeutics, Inc.

EWTX

$41.05 ▼ -3.43 (-7.72%) at close

7 Visible periods

19 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Edgewise Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.2B

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -36.7% ↘

FCF / Share $-1.40 ↘

Trailing P/E —

Price / Book 8.4x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-167.79M

↓ -25.4% —

FCF / Share Free cash flow per share

$-1.40

↓ -17.2% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	-12.4% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	7.6% Fair ↓ Fair Declining Year-over-year change in earnings per share Optimal: > 10%	-24.6% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-10.5% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	95.1% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	-25.4% Weak ↑ Weak Improving Year-over-year change in net income	-33.6% Weak ↑ Weak Improving Year-over-year change in net income	-48.1% Weak ↑ Weak Improving Year-over-year change in net income	-58.0% Weak Weak Year-over-year change in net income	-150.0% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-17.2% Weak ↓ Weak Declining Year-over-year change in free cash flow	22.1% Good ↑ Good Improving Year-over-year change in free cash flow	-41.2% Weak ↓ Weak Declining Year-over-year change in free cash flow	-19.2% Weak Weak Year-over-year change in free cash flow	95.5% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Effective Tax Rate (%) (%)	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—
FCF / Net Income (x)	0.86x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.98x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-36.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-34.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-28.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-16.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-12.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	40.6% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-34.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-32.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-33.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-19.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-15.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-13.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-32.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-314%)	-29.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-294%)	-31.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-309%)	-19.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-230%)	-15.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-204%)	51.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+242%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Net Debt (USD)	$-61.15M	$-41.67M	$-86.10M	$-21.99M	$-15.57M	$-104.92M	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Basic EPS, GAAP (USD)	$-1.63	$-1.45	$-1.57	$-1.26	$-1.14	$-23.17	—
Free Cash Flow per Share (USD)	$-1.40	$-1.19	$-1.53	$-1.09	$-0.91	$-20.08	—
Book Value per Share (USD)	$4.92	$4.84	$4.53	$5.48	$5.54	$-33.11	—
Tangible Book Value per Share (USD)	$4.92	$4.84	$4.53	$5.48	$5.54	$-33.11	—
Basic Weighted Avg Shares (shares)	102.93M	92.41M	63.72M	53.59M	37.53M	739,004	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$516.01M	$451.62M	$310.23M	$340.41M	$273.25M	$125.30M	—
Total Equity (USD)	$522.26M	$459.22M	$318.83M	$346.72M	$274.38M	$-33.42M	$-16.85M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Depreciation Expense (USD)	$2.08M	$2.07M	$1.55M	$368.00K	$272.00K	$185.00K	—
Net Income, GAAP (USD)	$-167.79M	$-133.81M	$-100.16M	$-67.64M	$-42.81M	$-17.12M	—
Operating Cash Flow (USD)	$-143.82M	$-109.03M	$-91.95M	$-52.63M	$-33.51M	$-14.63M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters

Edgewise Therapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare EWTX with peers